Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of mongersen in active Crohn's disease
MOH_2017-07-17_000314Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2017
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mongersen in Crohn's disease (3 arms), sponsored by Celgene Corporation. Started Jun 2017; status: completed.
02
Drugs
mongersen
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2017-07-17_000314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-17_000314.